6335-15-5Relevant articles and documents
Synthesis, Structure, Reactivity, and Catalytic Activity of Cyclometalated (Phosphine)- and (Phosphinite)ruthenium Complexes
Sun, Ruichen,Chu, Xiaodan,Zhang, Shaowei,Li, Tongyu,Wang, Zhuo,Zhu, Bolin
, p. 3174 - 3183 (2017/07/22)
Reactions of naphthyl- and o-methylphenyl-substituted phosphines with [RuCl2(p-cymene)]2 resulted in the corresponding phosphine-substituted ruthenium dichlorides (1a,b and 3). When the reactions of aryl-substituted phosphines or pho
3 -MONOSUBSTITUTED TROPANE DERIVATIVES AS NOCICEPTIN RECEPTOR LIGANDS
-
Page/Page column 13, (2008/06/13)
Compounds of the formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 is aryl, arylalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, cycloalkylalkyl, heterocycloalkyl, heterocycloalkylalkyl or alkyl, all optionally substituted; R
AZETIDINECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CB1 RECEPTOR MEDIATED DISORDRS
-
Page 58, (2008/06/13)
Compounds of formula (I) and their use in therapy, particularly for the treatment of a disorder mediated by CB1 receptors, such as obesity, wherein: R1 is aryl or heteroaryl; R2 is alkyl, aryl or heteroaryl; R3 is alkyl, aryl, heteroaryl, NR9R10, OR 15, or NR16C(O)R17;Y is C=O, C=S, SO2, or (CR7R8)p; m = 1 or 2; n = 1 or 2; and p=1,2,3 or 4, R7 to R17 being as defined in the specification; wherein if -Y-R3 is -C(O)NH(alkyl) then: R1 and/or R2 is selected from heteroary1; and/or m and/or n is 2; and/or R11 and/or R12 is lower alkyl, or a pharmaceutically acceptable salt or prodrug thereof.